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Systemicjuvenileidiopathicarthritis(sJIA)constitutesasmallpartofjuvenileidiopathicarthritis(JIA),yethasadisproportionally
higher rate of mortality. Despite being grouped under JIA, it is considered to be a multifactorial autoinﬂammatory disease.
The objective of this paper is to review the epidemiology, pathogenesis, genetics, clinical manifestations, complications, therapy,
prognosis, and outcome of sJIA. The presentation and clinical manifestations of sJIA have not changed much in the past several
decades, but the collective understanding of the pathogenesis and the development of new targeted therapies (particularly the
biologic agents) have transformed and improved the disease outcome for children with sJIA.
1.Introduction
In 1897, Sir George Fredrick Still described 22 children,
12 of whom had a unique constellation of symptoms that
included chronic arthritis, adenopathy, splenomegaly, and
fevers [1]. Initially bearing his name, and later known by
other names (systemic juvenile rheumatoid arthritis, sys-
temic juvenile chronic arthritis), this entity is now known as
systemic arthritis [2]. To allow for improved identiﬁcation
and research the International League of Associations of
Rheumatology (ILAR) proposed a classiﬁcation for JIA [2,
3]. To fulﬁll the criteria for systemic juvenile idiopathic
arthritis (sJIA) a child must be under 16 years of age and
have “arthritis in one or more joints with or preceded by
fever of at least 2 weeks’ duration that is documented to
be daily (“quotidian”) for at least 3 days and accompanied
by one or more of the following: (1) evanescent (nonﬁxed)
erythematousrash,(2)generalizedlymphnodeenlargement,
(3) hepatomegaly and/or splenomegaly, (4) serositis” [3].
Exclusions include “(a) psoriasis or a history of psoriasis
in the patient or a ﬁrst-degree relative, (b) arthritis in an
HLA-B27 positive male beginning after the 6th birthday, (c)
ankylosingspondylitis,enthesitis-relatedarthritis,sacroiliitis
withinﬂammatoryboweldisease,Reiter’ssyndrome,oracute
anterior uveitis, or a history of one of these disorders in
a ﬁrst-degree relative, (d) the presence of IgM rheumatoid
factor on at least 2 occasions at least 3 months apart”
[3]. Despite being included under the inclusive umbrella of
juvenile idiopathic arthritis (JIA), it is likely that sJIA is a
diﬀerent disease, for it appears to be unlike the other forms
of JIA both in clinical presentation and its pathogenesis [4]
(refer to section under pathogenesis). In the following sec-
tionswewillreviewtheepidemiology,pathogenesis,genetics,
clinical manifestations, complications, therapy, prognosis,
and outcome of sJIA.
2. Age of Onset, Genderand Ethnicity
By deﬁnition, sJIA can present at any point until the age of
16; however, in a recent study by Behrens et al., 74 out of
136 patients presented between 0–5 years of age, and age 2
was the most common age at presentation (n = 17) [5].2 International Journal of Inﬂammation
Several studies showed that gender distribution is roughly
equal [5, 6]. Ethnic composition seen in sJIA patients from
Behrens et al.’s study parallels that of the population in the
stateofPennsylvania(with82%Caucasiansand14%African
Americans) [5].
3. Incidence and Prevalence
In a recent study by Modesto et al., the prevalence of sJIA
was3.5per100,000[7].Whenreviewingolderliterature,10–
20% of the cases of juvenile rheumatoid arthritis (JRA) was
comprised of systemic disease [8]; we are awaiting data from
more recent studies using the current classiﬁcation system.
Disproportionately, sJIA contributes about two-thirds of the
total mortality rate in JIA [9]. The incidence of sJIA ranges
between 0.4–0.9 per 100,000 per year (Table 1)[ 7, 10–15].
4.Pathogenesis andGenetics
Cytokine dysregulation is seen in sJIA. While interferon
γ levels are decreased, proinﬂammatory cytokines such
as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-
6), interleukin-8, monocyte chemoattractant protein-1, E-
selectin, and intracellular adhesion molecules levels are
elevated in sJIA [16–21]. Recently, the role of interleukin-
1β (IL-1β)i ns J I Ar e c e i v e da t t e n t i o n .E x c e s sI L - 1 β can result
in fever, anorexia, pain hypersensitivity, joint destruction,
vasculitis, and thrombosis [22]; its dysregulation can lead
to the clinical and laboratory ﬁndings of sJIA. In Pascual et
al.’s study, culturing healthy peripheral blood mononuclear
cells with serum of sJIA patients caused an increase in IL-
1 secretion; an increased production of IL-1β protein from
mononuclear cells of active sJIA patients was also seen [23].
IL-1β a p p e a r st oh a v eap i v o t a lr o l ea n dm a yb er e s p o n s i b l e
for the elevation in IL-6 [23].
IL-6 has an important role in aﬀecting the systemic
manifestations as well as arthritis in sJIA. Elevation of
IL-6 in both peripheral blood and synovial ﬂuid is seen;
its expression seems to correlate with disease activity and
parallel the fever curve [24]. Acute phase reactants (such
as C-reactive protein (CRP), serum amyloid A, ﬁbrinogen,
and ferritin) are stimulated by IL-6 [25]. It appears to be
responsible for the anemia seen in sJIA, as well as promote
theproductionofhepcidin[26].Hepcidinisproducedbythe
liver and is responsible for transmembrane iron transport;
when elevated, it prevents the release of iron from the
macrophages, hepatocytes, and enterocytes to the plasma,
thuscausingadecreaseinserumironlevels[26].Inaddition,
IL-6 may activate osteoclasts and cause osteoporosis, as well
as instigate cartilage damage [27].
Other cytokines that may play a role in sJIA are
interleukin-18 (IL-18) [28], myeloid-related protein (MRP)-
8 and MRP-14 [29, 30], macrophage migratory inhibitory
factor (MIF) [31], and interleukin 4-1098 T/G polymor-
phism [32]. In addition, dysregulation in the expression
of anti inﬂammatory cytokine interleukin-10 (IL-10) (via
promoter polymorphism) seems to play an important part
in sJIA [33].
Table 1: Incidence of sJIA (per 100,000/year) in the literature.
Study sJIA incidence
100,000/year
Modesto et al. 2010 [7]0 . 5
Pruunsild et al. 2007 [10]0 . 9
Berntson et al. 2003 [11]0 . 6
Huemer et al. 2001 [12]0 . 4
Kaipiainen-Seppnen and Savolainen 2001
[13] 0.9
Malleson et al. 1995 [14]0 . 4 9
Pelkonen et al. 1994 [15]0 . 4 7
Innate immune abnormalities in sJIA make it likely to
be grouped with the autoinﬂammatory diseases [34], and
indeed, according to the fourth international congress on
the systemic autoinﬂammatory diseases, sJIA is a complex
multifactorial autoinﬂammatory disease [35]. The lack of
strong major histocompatibility complex association can be
seen both in sJIA and autoinﬂammatory diseases [34].
Pyrin (also known as marenostrin) is a 781 amino acid
protein encoded by the familial Mediterranean fever gene
(MEFV) found on chromosome 16p [36, 37]. Pyrin plays a
role in the downregulation of inﬂammation [38, 39]. A reg-
istry of MEFV gene mutations is kept in the online database
Infevers [40], and approximately 180 sequence alterations
have been identiﬁed, out of which, 5 mutations are the
most common ones [41]. When MEFV gene mutations
occur, pyrin’s function is compromised, and uncontrolled
inﬂammation is potentiated [39]. It is not surprising that
some of the genetic defects seen in sJIA are also seen in the
autoinﬂammatory syndromes [39, 42], and particularly in
FMF, where mutations in the MEFV gene are present [43]. In
ethnic groups where FMF is common, the following diseases
have an increased rate of MEFV gene mutations (compared
with an ethnically matched population): Polyarteritis nodosa
[44], Henoch-Sch¨ onlein purpura [45], and Behc ¸et’s disease
[46–49]. A higher rate of MEFV gene mutations was seen
in patients with sJIA in comparison with ethnically matched
population (P<0.01) [39]. Interestingly, even when
only one allele is aﬀected by mutations or polymorphism,
subclinical inﬂammation can be seen [50, 51]. It is possible
that mutations in the MEFV gene prompt a carrier to either
develop sJIA or have a more severe course. In a recent study
by Ayaz, the MEFV mutation frequency in sJIA patients
was seen in 14.28% (signiﬁcantly higher than in the general
population (P<0.01)); the most common mutation was
M694, which appeared in frequency of 10% [39].
It has been postulated that a genetic association between
sJIA and macrophage activation syndrome (MAS) exists via
a mutated perforin gene (PRF1) [52–54] and polymorphism
of both MUNC13-4 [55] and interferon regulatory factor 5
(IRF5)[56]genes.However,Donnetal.studiedgenesknown
to be associated with the familial form of hemophagocytic
lymphohistiocytosis (HLH) (HLH and MAS will both be
discussed more under the section on complications) and
did not see an increased susceptibility to sJIA [57]. OnlyInternational Journal of Inﬂammation 3
a limited number of genes were analyzed, and furthermore,
thegeneticassociationofMASinanexistingsJIApatientwas
not studied [57].
5. Features at Presentation
The most common presenting feature is fever, followed
by arthritis and rash. Less frequent are lymphadenopathy,
pericarditis, and hepatosplenomegaly [5, 58]. Most patients
present with laboratory ﬁndings indicative of inﬂammation:
elevated erythrocyte sedimentation rate (ESR) and CRP
[5, 58], leuko- and thrombocytosis, and elevation in liver
transaminases, as well as anemia [5]. Elevation of D-dimers
[5, 59], ferritin, and aldolase [5]i ss e e n .
Some patients’ initial presentation of sJIA is that of life-
threatening MAS (discussed further under complications).
The clinical ﬁndings are very similar to those of both sJIA
and sepsis, with unremitting fever ≥ 38◦C, central ner-
vous system manifestations, hemorrhage, lymphadenopathy,
hepatosplenomegaly, rash, serositis, and myocarditis [60].
The laboratory ﬁndings include thrombocytopenia, hyper-
ferritinemia, elevated liver enzymes, leukocytosis, normal
or decreased ESR, hypoﬁbrinogenemia, and hypertriglyc-
eridemia [61].
6. ClinicalManifestations
6.1. Fever. Fever is the most common symptom at time
of initial presentation. According to Behrens et al., 98% of
patients present with fever [5], and in a cohort study from
the United Kingdom, France, and Spain, 100% of patients
presented with fever (this was an inclusion criteria) [58].
Classically, it has been described as a quotidian fever that
spikes to greater than 39◦C once or twice daily, typically
occurring in the evening [8, 62–64]. Although the quotidian
pattern is one of the ILAR criteria for diagnosis of sJIA,
Behrens et al.’s study showed diﬀerent patterns. The classic
pattern is only seen in 37% of the patients during initial
presentation; others exhibit morning fevers (12%), bi-daily
fevers (15%), intermittent fevers (27%), and unremitting
fevers (5%) [5], as well as not reaching 39◦C[ 5, 62]. In
addition to the fevers, some children rapidly defervesce and
a t t a i ns u b n o r m a lt e m p e r a t u r e s[ 8, 64, 65]. While the child
is febrile, other symptoms such as arthritis, rash or serositis
can worsen and cause signiﬁcant disturbance of daily life;
however, once the child has defervesced, it is not unusual to
see a resumption of regular activities [8, 62, 66].
6.2. Musculoskeletal. Arthritis is the second most common
presenting symptom [5], and arthralgias can precede the
arthritis[65,66].AccordingtoBehrensetal.,88%ofchildren
presentedwitharthritis[5].Inthosecaseswherearthritiswas
notfoundinitially,ittypicallyappearedwithinafewmonths;
infrequently the arthritis will not present until several
years later [8]. In Behrens et al.’s study, equal distribution
between polyarticular and oligoarticular patterns was noted
at presentation (41% polyarticular, 40% oligoarticular, and
7% monoarticular presentation) [5]; however, in a European
study the ratio diﬀers, and an oligoarticular pattern is found
on presentation twice as often as a polyarticular pattern
[58]. The wrists, knees, and ankles are primarily the most
commonly involved joints on initial presentation [5, 8].
Despite being mostly asymptomatic, temporomandibular
jointarthritiscanalsobeseen[67,68].Overthecourseofthe
disease, chronic progressive arthritis is seen in approximately
one third to one half of the patients [65, 69], and ultimately
polyarticular joint involvement is found in most of these
cases[8].Cervicalspinearthritisaswellashiparthritis(often
bilateral and destructive) can also be seen [8].
Another musculoskeletal manifestation of sJIA is the
development of synovial cysts [70–73]. These cysts occur
more frequently in the upper extremities [70]; they normally
resolve on their own, but they may rupture and present as
pseudothrombophlebitis [8]. Lymphedema can also occur as
a rare musculoskeletal manifestation [8, 74]. It is likely that
inﬂammation of the lymphatic vessels causes this painless
swelling [8]. For the most part, pharmacological treatment
is not indicated, but compression stocking may improve the
lymphedema [8].
6.3. Rash. Sir George Fredrick Still himself did not describe
a rash in the depiction of the disease. It was not until more
than 50 years later that attention was given to this unique
ﬁnding [66, 75]. Evanescent in nature and bright salmon
pink in color, this rash is morbilliform, macular, often with
central clearing, and tends to be migratory and widespread
[64, 75, 76]. It initially emerges mostly on the limbs and
trunkandlessontheface,neck,palms,andsoles[66,75,76].
The rash is ﬂeeting (vanishes within a few minutes to a
few hours), and it correlates with the acute febrile episodes
[64, 75, 76]. According to Behrens et al. 81% of patients
presented with a rash [5]. Modesto et al., reported that a rash
was seen in 89% of patients with good prognosis and 79%
in patients with bad prognosis [58]. Most often the rash is
nonpruritic [76], but in about 5% of the patients pruritus
does occur [77, 78]. In addition, the Koebner phenomenon
(emergence of linear distribution of lesions next to site of
injury) can occur [75, 76].
During the height of the rash, histological ﬁndings reveal
only sparse perivascular inﬁltration of mononuclear cells
and neutrophils [75, 76]; normal skin biopsy is seen in
patients whose rash had resolved [76]. Just as in other
inﬂammatory processes (such as psoriasis, lichen planus,
cutaneous lupus erythematosus, or wound healing [79, 80]),
activated keratinocytes expressing proinﬂammatory S100-
proteins—MRP8 and MRP14 are seen in the rash of sJIA
[29]. In another study by Frosch et al., MRP8 and MRP14
were found to be generalized and not limited only to the site
of the rash; if the patient responded to treatment, MRP8 and
MRP14 normalized [81]. In addition, during active disease,
leukocytes were seen within the epithelium of sweat gland
ducts [81].
Persistent ﬁxed pruritic papules and plaques with ﬁne
scales were previously described and were reported to have
unique histological ﬁndings of dyskeratosis in the superﬁcial
layers of the epidermis and minimal superﬁcial dermal4 International Journal of Inﬂammation
neutrophilic inﬁltrate [82] .F i n a l l y ,m a l a rr a s hi ns J I Aw a s
described in a single case report [83].
6.4. Lymphadenopathy. Generalized lymphadenopathy is a
common ﬁnding [8, 65]. In Behrens et al., 31% of
the patients had initial presentation of lymphadenopathy
[5]; in Modesto et al., 24% out of the good prognosis
group and 51% of the bad prognosis group presented
with lymphadenopathy [58]. The lymphadenopathy consists
of painless rubbery mobile nodes and can be found in
epitrochlear and axillary nodes [8, 65]; at times it can
appear so striking that neoplasm may be suspected [84]. In
comparison, mesenteric adenitis can be painful [8], and in
the past it has led to operative interventions on children
who were misdiagnosed with a surgical abdomen [65].
On radiographic studies, para-aortic adenopathy can be
identiﬁed, and histologically, reactive changes are noted in
the nodes [8].
6.5.Hepatosplenomegaly. Splenomegalyoccursinabout50%
of the cases [8]; hepatomegaly does not occur as often
[64], yet when it does, it frequently occurs when the
disease is active [8]. Abnormal liver function can be seen
prior to beginning therapy (but most patients did receive
non-steroidal anti-inﬂammatory drugs for their ongoing
fevers [85] which may cause this abnormality); however,
clotting factors seem to be unaﬀected [8]. On histological
examination periportal inﬁltrates of inﬂammatory cells were
noted [85]. Hepatosplenomegaly needs to be monitored, as
its progression may be related to amyloidosis [8].
6.6. Serositis. The most common type of serositis is peri-
carditis [8, 86]. In Behrens et al.’s study 10% of the patients
presented with pericarditis [5]. According to Modesto et
al., serositis (not speciﬁed) was seen in 14% of those who
had good prognosis and 16% of those with bad prognosis
[58]. It is typically recurrent but benign [87]. It often
develops early in the course of sJIA and can manifest itself
before the appearance of arthritis [8, 66, 87]. Children
who have pericarditis may have nonspeciﬁc ﬁndings such
as tachycardia and dyspnea, but may also have a friction
rub [86]. Pericarditis may be an ominous sign of evolving
myocarditits, which has more serious and potentially fatal
complications of cardiomegaly, congestive heart failure, and
arrhythmias [65, 88–90]. In a 1992 study by Goldenberg et
al., which investigated symptomatic cardiac manifestations
in JRA, 13 out of 172 patients were identiﬁed (11 of whom
had sJIA); from the sJIA patients, pericarditis was recorded
in 5, myopericarditis in 4 and isolated myocarditis in 2
patients [86]. Asymptomatic pleuritis and pleural eﬀusions
can present together with pericarditis or independently [8,
65].
Peritonitis is a rare manifestation of sJIA and was seen in
two children, one during the ﬁrst week of presentation, and
the other 10 years after diagnosis [91].
6.7.Other Manifestations. Althoughrare,centralnervous sys-
tem manifestations such as seizures, meningismus, as well
as irritability and decreased level of consciousness were
previously described [92]. Ocular manifestations can be seen
in sJIA, and uveitis is one of the complications [93]. A
case report by Ishihara et al. described a patient with sJIA
who developed bilateral panuveitis 3 years after her initial
presentation [93]. In addition, Brown’s syndrome (restricted
movement of the superior oblique tendon) was seen in 3
children and reported in two case reports [94, 95]. Although
nasal septum perforation is a complication of rheumatic
illness, it was described in only 3 children with sJIA in a case
series [96].
With the exception of pleuritis, pulmonary manifesta-
tions are also rare. Pulmonary function test abnormalities
were reported in the 1980’s by Wagener et al. [97]. In a
cross-sectional study, Van Der Net et al. described restrictive
pulmonary function in 8 out of 17 patients showing
decreasedtotallung capacity;in 2 additional patients normal
(yetlower)totallungcapacitywasseen[98].Obstructionwas
not seen, as the Tiﬀeneau index (FEV1/FVC × 100%) was >
83% in all of the patients [98]. Interstitial pulmonary disease
was reported by Athreya et al. [99]. Pulmonary hypertension
was described in one case report [100], and pulmonary
interstitial and intra-alveolar cholesterol granulomas were
described in a 2001 case report [101].
The clinical presentation of sJIA and Kawasaki disease
(KD) can be similar in young children. In a recent study
from Binstadt et al., 5 out of 12 sJIA patients who had an
echocardiogram that fully evaluated the coronary arteries on
initial presentation had coronary artery dilation, and out of
these, 2 patients had initially fulﬁlled the KD criteria [102].
Interestingly, a study by Maeno et al. showed that signiﬁcant
elevation of IL-18 levels was seen in sJIA, but not in KD or
other types of JIA [103].
7. DifferentialDiagnosis
With nonspeciﬁc clinical and laboratory ﬁndings, the dif-
ferential diagnosis of sJIA is extensive and should include
infectious as well as post infectious etiologies, connective tis-
sue diseases, vasculitis, malignancies, and autoinﬂammatory
syndromes [42].
8. Complications
8.1.Amyloidosis. Serumam ylo idAisanacut ep haser eactant
which is elevated with inﬂammatory processes. It is the pre-
cursor for serum amyloid A protein [104, 105]. Amyloidosis
isoneofthemostseverecomplicationsofsJIA.Forunknown
reasons, amyloidosis tends to be very rare in North America
and yet aﬀects a larger percentage of individuals in the UK
and Turkey (7.4% and 16%, resp.) [106, 107]. Deposition of
the protein has an eﬀect on vital organs such as the kidney,
liver, gastrointestinal tract, and heart [105]. Upon biopsy of
rectalmucosa,subcutaneousfat,gum,orkidney,amyloidosis
can be histologically recognized by using Congo red stain,
which reveals eosinophilic deposition; when employing
polarized light, the characteristic apple-green birefringence
surfaces [105, 108, 109]. The ﬁrst clinical sign of amyloidosisInternational Journal of Inﬂammation 5
is proteinuria, but it is often missed and nephrotic syndrome
is seen [8, 105]. Other symptoms that may suggest amyloi-
dosis are: hypertension, hepatospenomegaly, and abdominal
pain [8, 105]. Unless the inﬂammatory process of sJIA is
successfully suppressed and amyloidosis reverses, death from
progressive renal failure in those children with amyloidosis
can result [8, 105]. Immonen et al. examined the long-term
outcome of 24 patients with amyloidosis; sJIA was seen in
11/24 patients (46%). The overall 5 year survival rate was
88%, and 10-year survival rate was 75%. Out of the 24
patients with all subclasses of JIA, 10 died. Although the
mortality for the diﬀerent types of JIA was not speciﬁed,
overall, a higher mortality was seen in patients who were
treated solely with corticosteroids, while those who were
treated with disease modifying antirheumatic drugs and/or
cytotoxics had a better survival (P = 0.001) [110].
8.2. Macrophage Activation Syndrome. In 1985 Hadchouel
et al. described a life-threatening complication of sJIA
[111] for which the term MAS was later coined [112].
Uninhibited production and activation of both macrophages
and T lymphocytes cause fever, rash, pancytopenia, hepatic
insuﬃciency, coagulopathy, lymphadenopathy, and neuro-
logical dysfunction [113, 114]. MAS is not a unique entity,
but rather a term used to describe a form of secondary
HLH when it is seen in a rheumatic illness [115–117]. The
incidence of MAS in the context of sJIA is estimated to
be anywhere from 6.7%–13% [60, 118], and mortality rate
ranges between 8–22% [118, 119]. As the symptomology of
MAS is almost identical to that of sJIA, it is very diﬃcult
to diagnose. Some of the laboratory ﬁndings that are useful
in distinguishing the two are the presence of cytopenias
a n dn o r m a lE S Rn o t e di nM A S[ 118]. Nevertheless, it was
recently shown that multiple sJIA patients had evidence of
hemophagocytosisonbonemarrowexaminationbutdidnot
have any clinical ﬁndings [60]. It is now believed that sJIA
and MAS are possibly the two extremes of similar entities,
where sJIA represents hidden or inactive MAS [4, 5].
9. Treatment
Historically, the management of sJIA included the use of
nonsteroidalantiinﬂammatorydrugs(NSAIDs),intravenous
immune globulin (IVIG), corticosteroids, methotrexate,
anti-TNF, cyclosporine, thalidomide, cyclophosphamide,
and autologous stem cell transplantation [42, 120–123].
IVIG was initially encouraging, but in further studies, it was
noted to perhaps be useful only for particular subsets of
childrenwithearlysystemicdisease[124].Althoughshowing
signiﬁcant eﬃcacy in other subtypes of JIA, methotrexate
did not show adequate response in sJIA [125–127]. Anti-
TNF agents were shown to have only a partial response
[128–132]. With the recent expanding understanding of sJIA
pathogenesis, the treatment has changed tremendously. A
moretargetedtherapyintheformofbiologicblockingagents
transformed the treatment of sJIA [133, 134].
9.1. NSAIDs. In sJIA, NSAIDs are used for the management
of pain, stiﬀness, and fever [135]. Historically, aspirin was
used; however, the risk of intoxication [62]a sw e l la s
development of Reyes syndrome promoted the replacement
of aspirin with other NSAIDs [136–139]. Ibuprofen, meloxi-
cam, naproxen, tolmetin, and celecoxib are approved by the
Food and Drug Administration (FDA) for treatment of JIA
[140]. Gastrointestinal adverse reactions such as gastritis
and duodenitis are common [141, 142]. Pseudoporphyria
associated with naproxen therapy can be seen in those
children with light complexion and light hair. As permanent
scarring may occur, awareness of this adverse reaction is
important [143–145].
9.2. Corticosteroids and Cyclophosphamide. Although not
considered to be disease modifying, systemic corticosteroids
are often used when patients experience a preponderance of
systemic features [135]. Kimura et al. studied the eﬃcacy
and side eﬀects of high-dose alternate day prednisone and
concluded that it was a valuable therapy with minimal
adverse reactions [146].
Intravenous pulsed methylprednisolone is also useful
in treating sJIA patients. In Adebajo and Hall’s study,
pulse steroids (30mg/kg with a maximum of 1g) was
given to sJIA patients: 55% of the patients had full
resolution of systemic manifestations, and 45% of the
patients had reduction in arthritis; furthermore, 16% of
the patients obtained remission [147]. Prolonged use of
corticosteroids in children has multiple signiﬁcant adverse
reactions such as inhibition of growth, immunosuppression,
striae, delayed puberty, osteoporosis, cushingoid habitus,
myopathy, cataracts, hypertension, psychologic eﬀects, and
others, all of which can immensely aﬀect the pediatric pop-
ulation [148–151]. Because of the considerable undesirable
eﬀects of corticosteroids, switching to an eﬀective steroid
sparing agent is critical in these patients.
Humoral immunity is aﬀected by high-dose cyclophos-
phamide [152], and high-dose corticosteroids cause decrease
in E-selectin, ICAM-1 [153], CD11b, and CD18 in the
synovial membrane and neutrophils [154]. Shaikov et al.
described an open-label trial in 18 children with sJIA using
combination methylprednisolone and cyclophosphamide,
with signiﬁcant improvement in systemic and articular
manifestations[122].WallaceandSherryreported4children
who improved after receiving intravenous pulse cyclophos-
phamide and methylprednisolone [121]. In 3 of the 4
patients, remission was obtained, and prednisone dose
was decreased by ≥25%, and in all patients improvement
was seen clinically (with ≥50% improvement in joint
count and improved linear growth), as well as in their
laboratory parameters [121]. Lehman reported 6 children
treated with intravenous cyclophosphamide with minimal
improvement [155]. Lastly, Chen et al. reported of 4 sJIA
patients treated with intravenous cyclophosphamide and
methylprednisolone; 2 of the patients achieved remission, 1
had shown improvement, and 1 did not improve [156].
9.3. Biologics
9.3.1. IL-1 Inhibitors: Anakinra, Rilonacept, and Canakin-
umab. IL-1 inhibition can be achieved via 3 ways: IL-16 International Journal of Inﬂammation
receptor antagonist, anakinra; IL-1R-IL1RacP-Fc fusion pro-
tein, rilonacept; or IL-1β antibody, canakinumab [157].
Initial reports using anakinra were promising with rapid
improvement and remission of patients [133, 134]. However,
later reports indicated that some patients did not respond as
well to this treatment [158, 159]. In Gattorno et al.’s 2008
study, 10/22 (45%) of patients responded well to the therapy,
11/22 (50%) had incomplete response or no response to the
therapy,and1/22(5%)couldnotbeclassiﬁedaseither[159].
In Lequerr´ e et al., at the last follow up, complete response
w a ss e e ni n4 / 2 0( 2 0 % ) ,p a r t i a lr e s p o n s es e e ni n5 / 2 0( 2 5 % ) ,
and no response seen in 8/20 (40%) of patients (of the 3
patients not accounted for, 1 had a complete response at
3 months but did not have a reported follow up, and two
were seen at two months with no response and did not
have a reported follow up) [158]. In Ohlsson et al.’s study,
6/7 (86%) responded well to anakinra, while 1/7 (14%)
did not have a good response [160]. In Zeft et al.’s 2009
study, 8/33 (24%) of patients did not have a good response
[161]. A recent multicenter report of 46 patients treated with
anakinra showed signiﬁcant improvement; by 1 month of
treatment, 86% of patients experienced abatement of fever
and rash, and 84%, 63%, 83% and 71% of patients had
normalization of CRP, ESR, ferritin levels, and platelet count
respectively [162]. In that study complete response occurred
only in 59% of the patients, partial response in 39% of the
p a t i e n t s ,a n di n2 %l a c ko fr e s p o n s e[ 162]. Two theories
have risen to explain the diﬀerent therapeutic response.
Gattorno et al. postulated the existence of further classes in
sJIA [159], and Nigrovic et al. hypothesized less eﬃcacious
blockade of IL-1 in an established disease secondary to either
chronic inﬂammation (derived from ample supply of IL-
1), or secondary to independent action of IL-17, possibly
causing arthritis [162].
Rilonacept, the IL-1R-IL1RacP-Fc fusion protein (also
known as IL-1 trap), showed immense response in an
open label pretrial [163]. The selective IL-1β antibody
canakinumab treats genetic fever syndromes, thus identify-
ing this agent as a potential therapeutic modality for sJIA
[164].
9.3.2. Tocilizumab. Tocilizumab is a humanized monoclonal
antibody, targeting both membrane bound and soluble IL-
6r e c e p t o r s[ 165]. By binding to these receptors, signal
transduction through glycoprotein 130 is inhibited [166].
In 2003, Yokota reported the ﬁrst encouraging use of IL-6
inhibition in children [166]. In 2005, a phase II trial with
tocilizumab showed JIA 30%, 50%, and 70% improvement
accordingtoacoresetofresponsevariablesin10/11(90.9%),
10/11(90.9%),and7/11(63.6%)patients,respectively[167].
This deﬁnition of improvement was based upon the ACR
Pediatric (ACR Pedi) 30 criteria, alternatively known as
JRA, JIA, or Giannini’s criteria of improvement [130, 168,
169]. It is an outcome measure for improvement deﬁned
as the following: a 30% improvement of at least 3 out
of the following 6 core variables and no more than 30%
worsening in one of them: (1) physician global assessment
of disease activity; (2) parent/patient global assessment of
overall well-being (each scored on a 10cm visual analog
scale); (3) functional ability; (4) number of joints with active
arthritis; (5) number of joints with limited range of motion,
(6) ESR [170]. Similarly additional outcome measures for
improvement were later extrapolated: ACR pedi 50, 70, and
90, using the same guidelines as for the ACR Pedi 30 but
deﬁning a 50%, 70%, and 90% improvement in 3 of the 6
variables respectively, with no more than a 30% worsening
in one variable [168, 169].
In 2005, an open-label phase II trial examining sin-
gle ascending doses of tocilizumab had also shown good
response: JIA 30%, 50%, and 70% improvement was seen
in 11/18 (61%), 8/18 (44%), and 3/18 (17%) [171]. A 2008
study by Yokota et al. showed an ACR Pedi 30, 50, and 70
responseratein51/56(91%),48/56(86%),and38/56(68%),
respectively at the completion of the open-label phase, where
all patients received 3 doses of 8mg/kg of tocilizumab
every two weeks [172]. Out of the 56 patients, only 43
continued to the double-blind phase (3 patients developed
antitocilizumab IgE antibodies, one had an anaphylactoid
reaction, one had a gastrointestinal hemorrhage, and one
h a dl a c ko fe ﬃcacy). It was reported that in comparing the
tocilizumab treatment group and the placebo group, the
ACR Pedi 30, 50, and 70 responses were: 16/20 (80%), 16/20
(80%), 15/20 (75%) and 4/23 (17%), 4/23 (17%), and 3/23
(13%), respectively. In the open-label extension of the trial,
ACR Pedi 30, 50, and 70 were achieved by 47/48 (98%),
45/48(94%),and43/48(90%),respectively[172].Lastly,ina
recent phase 3 trial, comparing tocilizumab treatment group
a n dp l a c e b og r o u pa f t e r1 2w e e k so ft h e r a p y ,D eB e n e d e t t i
et al. reported absence of fever and JIA ACR 30 to be 85%
versus 24% (P<0.0001); furthermore, JIA ACR 50, 70, and
90werecomparedbetweenthetreatmentandplacebogroups
and were 64/75 (85%), 53/75 (71%), 28/75 (37%) versus
11/37 (11%), 3/37 (8%), 5/37 (2%), respectively [173]. In
April 2011, the FDA approved the use of tocilizumab in sJIA
patients older than 2 years of age [174].
9.3.3. Abatacept. Abatacept is a fusion protein that blocks
the CD80 or CD86 interaction with CD28, which alters
the costimulatory signal, thus inhibiting T-cell activation
[175]. In 2008, a study by Ruperto et al. showed ACR Pedi
30% or more improvement in 65% of the systemic arthritis
group, but the study excluded children with active systemic
manifestations for the preceding 6 months [168]. In Ruperto
et al.’s long-term extension, abatacept was again reported to
have good response rate; the ACR Pedi 30, 50, 70, 90 and
inactive disease response rate in patients with sJIA without
systemicmanifestationswere88%,88%,63%,13%,and25%
correspondingly [176]. In a later report that year, Ruperto
et al. discerned improvement in health-related quality of life
(HRQOL) in JIA patients treated with abatacept (in which
about 20% of the patients that were studied had sJIA) [177].
9.3.4. Combination Therapy Anakinra and Abatacept. An
anecdotal report of a combination therapy of anakinra and
abatacept in 4 children with recalcitrant sJIA described
improvement of their symptoms, with no signiﬁcant adverse
reactions [178].International Journal of Inﬂammation 7
9.3.5. Antitumor Necrosis Factors Antibodies (Anti-TNF).
There are three diﬀerent types of antitumor necrosis factor
(anti-TNF) therapies: etanercept: a soluble TNFα receptor
[169, 179, 180], Inﬂiximab: a chimeric monoclonal TNFα
antibody, and Adalimumab: a humanized monoclonal anti-
body.
The results from Lovell et al.’s 2000 study comparing sJIA
patients’ ﬂare rate between placebo and etanercept therapy
were encouraging, with 7/8 (88%) patients on placebo
having a ﬂare, and 4/9 (44%) of those on etanercept having a
ﬂare (statistically signiﬁcant P<0.001) [181]. Several later
studies show that patients with sJIA appear to have only
partial response to anti-TNF agents [128–132].
In 2003 Lovell et al. published interim results from
an ongoing multicenter study examining etanercept, and
reported improvement rates in JRA (30%, 50% and 70%).
In the per protocol group at the end of the 2nd year,
30% improvement was seen in 10/12 patients (83%), 50%
improvement was seen in 9/12 patients (75%), and 70%
improvement was seen in 8/12 patients (67%); in their mod-
iﬁed intent-to-treat group (which included the patients who
discontinued therapy) 30% improvement was seen in 10/17
patients (59%), 50% improvement was seen in 9/17 patients
(53%), and 70% improvement was seen in 8/17 patients
(47%) [169]. In Horneﬀ et al.’s 2004 study, a lower eﬃcacy
was seen in sJIA patients, where Giannini’s criteria of 30%,
50%,and70%improvementwasseenin48%,33%,and11%
of the patients, respectively, after 1 month of treatment with
etanercept, and after 3 months of treatment, improvement
wasseenin63%,39%,and24%[130].InKimuraetal.’s2005
study examining etanercept therapy, 37/82 (45%) patients
had poor response (<30% improvement), 7/82 (9%) had a
fair response (30–<50% improvement), 11/82 (13%) had a
good response (50–<70% improvement), and 27/82 (33%)
had an excellent response (>70% improvement), where the
response was deﬁned as a percentage decrease from baseline
of the following: steroid dose, count of actively involved
joints, inﬂammatory markers (ESR, CRP, or platelet count),
and physician global assessment of disease activity score,
rather than the ACR pedi response criteria [131]. In Russo
and Katsicas’ 2009 study, patients were treated initially with
etanercept, but if improvement was not seen, patients were
switched to therapy with either inﬂiximab or adalimumab.
The ACR pedi 30, 50, 70, and 90 criteria were used to assess
clinical improvement and were seen in 35 (78%), 28 (62%),
21 (47%), and 14 (31%) of patients, respectively [132]. See
Table 2. In Quartier et al.’s 2003 study, it was recognized
that in comparing the 30% improvement rate between sJIA
and oligoarticular or polyarticular JIA, those with sJIA had
a greater likelihood of not reaching the 30% improvement
(withP values of 0.0002 and 0.0031, resp.). Whencomparing
the 50 and 70% improvement rate, sJIA also had a signiﬁcant
risk of not attaining that improvement level in comparison
with oligoarticular onset JIA but did not diﬀer in risk value
from polyarticular onset JIA [129].
In a 2003 Lovell et al.’s study it was reported that out
of the 5 sJIA patients who withdrew from the study, 4 had
suboptimal clinical response, and 1 had an adverse event
[169]. In the 2006 extension study, it was reported that 19
patients entered the extension study, and only 6 patients
stayedintheextensionstudyfor≥4years(3ofthe13patients
withdrew secondary to lack of eﬃcacy) [179]. In the 2008
open-label extension it was reported that 19 patients had
entered the trial, but only 5 entered the 8th year [128], In
Horneﬀ et al.’s 2004 study, 17 of the 66 sJIA patients enrolled
withdrew from the trial, where ineﬃcacy of therapy was
the reason for discontinuation in 14 out of the 17 patients,
adverse eﬀectswere seen in 2 patients and 1 patient withdrew
for other reasons [130]. In Kimura et al.’s 2005 study, disease
ﬂares were seen in 37/82 patients (45%) in all levels of
therapeuticresponse;however,theyweremorelikelytooccur
in those who responded poorly to treatment (25/37 patients
(68%)) than in those who had an excellent response (7/27
patients (26%)). Cessation of treatment occurred in 29/82
patients (35%) mainly secondary to ineﬃcacy or ﬂare in
72.4% of these patients [131]. Tynj¨ al¨ a et al.’s 2009 study
lookedatlengthofanti-TNFtherapyusage(eitheretanercept
or inﬂiximab). At 24 and 48 months 46% and 76% of
patients, respectively, had discontinued their medications.
Ineﬃcacy was the most common reason for discontinuation
in the sJIA group [182].
In Katsicas and Russo’s 2005 study, patients who had
previously failed therapy with etanercept were treated with
inﬂiximab. It was reported that the majority of patients did
not reach improvement with inﬂiximab; however, the one
patient who showed a response to inﬂiximab did not have
systemic manifestations at the onset of therapy [183]. A
statistical signiﬁcance (P = 0.03) was recorded in Russo and
Katsicas’ 2009 study between remission and both the absence
of systemic manifestations at the onset of anti-TNF therapy
and improvement after 3 months of therapy. In that study
64% (29/45) of patients showed an improvement after 3
months of treatment, and 73% (33/45) of patients displayed
an improvement after 6 months [132].
9.3.6. Rituximab. Rituximab is a chimeric monoclonal anti-
body againstCD20,targeting Bcells.Woutersetal.described
a higher B-cell activity in all types of JIA, including sJIA
[184]. There are several case reports detailing treatment of
sJIA with rituximab. Kasher-Meron et al. describe an 18-
year-old female with a 12-year history of sJIA that was
recalcitrant to therapy that responded well to therapy with
rituximab [185] .Ac a s es e r i e sb yN a r v ´ aez et al. described
three adult patients with unrelenting sJIA (duration of
disease between 18–27 years), all of whom had noteworthy
improvement with rituximab therapy; with the exception
of one patient with hypersensitivity reaction, no other
signiﬁcantadversereactionswereseen[186].LastlyFeitoand
Pereda described an 8-year-old female that responded well
to rituximab, in both systemic manifestations and articular
manifestations [187].
9.4. Cyclosporine. Cyclosporine is an immunomodulator
that inhibits the synthesis of IL-1, IL-2, TNF-γ,a n dα-
interferon [188–190]. The results of a 10-year prospective
study looking at the eﬃcacy of cyclosporine A showed
beneﬁt for some children with sJIA, but for the majority
complete remission was not achieved [191]. In a later8 International Journal of Inﬂammation
Table 2: Response to anti-TNF therapy in sJIA patients.
Study Response Number of patients Discontinuation
Lovell et al. 2003 [169]
(per protocol group∗)
Etanercept
At 24 months:
(i) JRA 30% deﬁnition of improvement seen in
83% of patients.
(ii) JRA 50% deﬁnition of improvement seen in
75% of patients.
(iii) JRA 70% deﬁnition of improvement seen in
67% of patients.
12 Not included
Lovell et al. 2003 [169]
(modiﬁed intent-to-treat
group∗∗)
Etanercept
At 24 months:
(i) JRA 30% deﬁnition of improvement seen in
59% of patients.
(ii) JRA 50% deﬁnition of improvement seen in
53% of patients.
(iii) JRA 70% deﬁnition of improvement seen in
47% of patients.
17 5 (29%)
Horneﬀ et al. 2004 [130]
Etanercept
At 1 month:
(i) Giannini’s criteria of 30% improvement seen
in 48% of patients.
(ii) Giannini’s criteria of 50% improvement seen
in 33% of patients.
(iii) Giannini’s criteria of 70% improvement seen
in 11% of patients.
At 3 months:
(i) Giannini’s criteria of 30% improvement seen
in 63% of patients.
(ii) Giannini’s criteria of 50% improvement seen
in 39% of patients.
(iii) Giannini’s criteria of 70% improvement seen
in 24% of patients.
66 17 (26%)
Kimura et al. 2005 [131]
Etanercept
Mean duration of treatment: 24.8 ±12.3m o n t h s
(3–70 months):
(i) Poor response (<30%) seen in 45% of patients.
(ii) Fair response (30 to <5 0 % )i n9 %o fp a t i e n t s .
(iii) Good response (50 to <70%) seen in 13% of
patients.
(iv) Excellent response (>70%) seen in 33% of
patients.
82 29 (35%)
Russo and Katsicas 2009 [132]
Etanercept initially, if no
improvement seen, inﬂiximab
or adalimumab were studied.
Treatment for at least 6 months:
(i) ACR Pedi 30 seen in 78% of patients.
(ii) ACR Pedi 50 seen in 62% of patients.
(iii) ACR Pedi 70 seen in 47% of patients.
(iv) ACR Pedi 90 seen in 31% of patients.
45
22 (49%) of patients
switched to a second
anti-TNF (either
inﬂiximab-17 patients, or
adalimumab-5 patients)
secondary to lack of
response in 9 pts and lack
of eﬃcacy subsequently.
Inﬂiximab was then
discontinued in 4 patients
secondary to lack of eﬃcacy
and in 6 patients secondary
to toxicity.
∗Per protocol group consisted of 43 patients (with pauciarticular, polyarticular or systemic JRA) who were treated with etanercept for 2 years at time of Lovell
et al.’s analysis. Out of the 43 patients in this group, 12 patients had systemic JRA.
∗∗Modiﬁed intent-to-treat group consisted of 51 patients (with pauciarticular, polyarticular or systemic JRA): 43 were included in the per protocol group,
7 withdrew secondary to an inadequate clinical response (of these, 4 had systemic JRA), and 1 withdrew secondary to an adverse reaction (that patient had
systemic JRA). Out of the 51 patients in this group, 17 patients had systemic JRA.International Journal of Inﬂammation 9
surveillance study, out of those patients who were still
receiving cyclosporine at their last reported visit, only 5%
have achieved full clinical response, while 63% had mild to
moderate activity and 32% had severe uncontrolled disease
[192]. Associated adverse reactions reported are hypertri-
chosis, elevated serum creatinine levels, gingival hyperplasia,
gastrointestinal irritation, and hypertension [192].
9.5. Thalidomide. Thalidomide prevents cytokine synthesis
by disturbing mRNA synthesis rather than blockade [193],
and is a known anti-inﬂammatory agent that suppresses
angiogenesis, cell adhesion molecule expression, TNF-α,I L -
1, IL-6, and nuclear factor-κG[ 194–196]. In 2002, Lehman
et al. reported on 2 children with intractable sJIA who
were treated with thalidomide therapy and had signiﬁcant
improvement [197]. In 2004, Lehman et al. reported of
13 additional children who were treated with thalidomide.
A response was seen in 11 children, and 10 of them had
JRA improvement scores ≥50% in concordance with the
preliminary deﬁnition of improvement in juvenile arthritis
[120, 170]. Statistically signiﬁcant decrease in prednisone
dosage, decrease in ESR, and increase in hemoglobin level
were seen [120]. In 2007 a 3-patient case series was
reported by Garca-Carrasco et al., where after therapy with
thalidomide, 3 recalcitrant patients entered remission [198].
10. 2011 American College of
Rheumatology Recommendations
In the recent 2011 American College of Rheumatology
recommendations for the treatment of sJIA, the recommen-
dations were made by identifying the patient as belonging
to one out of two distinct clinical groups: active systemic
features(withoutactivearthritis),oractivearthritis(without
active systemic features), and also by disease activity level
and by prognosis. For those patients with both active
systemic features and active arthritis, a recommendation
was not made, but use of the two recommendations was
suggested. Furthermore, recent therapeutic agents, such as
IL-6 inhibitors and other IL-1 inhibitors besides anakinra
were not included the recommendations as they were not
available [199].
For systemic arthritis with active systemic features but
no arthritis, initiating NSAIDs, systemic glucocorticoids,
or anakinra as initial therapy is dependent on disease
activity and prognostic features. Patients with low disease
activity and good prognostic features are recommended
the treatment of NSAIDs, followed by glucocorticoids and
anakinra. NSAIDs may be omitted for those patients with
either poor prognostic features or high disease activity.
For patients with high disease activity and without poor
prognostic features, initial therapy with systemic glucocor-
ticoids followed by anakinra when not responding well is
recommended. For patients with poor prognostic features,
initial therapy may be either systemic glucocorticoids or
anakinra [199]. Methotrexate was deemed inappropriate for
this group, and both thalidomide and calcineurin inhibitors
were of uncertain beneﬁt [199].
Treatment recommendations for systemic arthritis with
active arthritis but without active systemic features include
up to 1 month of NSAIDs with glucocorticoid joint injec-
tions. If no improvement or worsening, methotrexate was
the next therapy. After 3 months of methotrexate therapy,
dependent on disease activity, the patient can start on
either TNFα inhibitor or anakinra. After 4 months of TNFα
therapy, if the disease activity is still high or moderate
(but with poor prognosis), abatacept was recommended.
Calcineurin inhibitors were found to be unsuitable for this
g r o u po fp a t i e n t s[ 199].
11. Course, Prognosis,and Outcome
The course and outcome of sJIA can vary considerably,
ranging from a monocyclic course with good outcome,
to a more complicated one which involves considerable
morbidity or mortality. In approximately half the patients
withsJIA,amonocycliccourseisseen,andcompleterecovery
with minimal physical limitations can be achieved within 2–
4y e a r s[ 42, 69, 200]. Waning ﬂares of systemic involvement
and mild arthritis can be seen in those with relapsing course
[42]. Some patients achieve resolution of their systemic
features, but suﬀer from signiﬁcant persistent arthritis
which tends to resolve after about 5 years [201]. However,
approximately 30% of the patients suﬀer from devastating
destructive chronic polyarthritis that is responsible for most
of the morbidity and account for the worst prognosis in this
disease [69, 202]; resolution of the arthritis does not usually
occur by adulthood [42]. These patients tend to have more
severe systemic manifestations [203], and for about 23–30%,
systemic features persist for more than 10 years after initial
presentation [204, 205].
Systemic manifestations 6 months following presenta-
tion, thrombocytosis [206], hip involvement in the setting
of polyarthritis, and generalized lymphadenopathy in those
less than 8 years of age [58] are predictors of poor outcome.
Several studies have attempted to stratify the risk for
development of destructive arthritis suggest that early course
arthritis of the hips, cervical spine, and small joints of
the digits can indicate higher risk [203, 207]. In the past,
amyloidosis was a signiﬁcant risk factor for death [42], but
according to Immonen et al., new onset of amyloidosis in
sJIA was not seen in Finland since 1991 [110]. MAS is
a signiﬁcant complication, and mortality was seen in 8–
22% [118, 119]. Lastly, psychological complications such
as depression, anxiety, and social isolation are important
patient outcomes [208].
12. Conclusion
The clinical symptoms of sJIA have not changed signiﬁcantly
from 1897 when it was ﬁrst described by Still. The recog-
nition of the unique nature of sJIA in comparison to other
types of JIA as well as an increased collective understanding
of the pathogenesis, instigated signiﬁcant advancement in
treatment options oﬀered to these children. IL-1 blockade
revolutionized the treatment and outcome for sJIA patients.10 International Journal of Inﬂammation
With the discovery of novel and targeted biologics, the
pediatric rheumatologist is presented with several choices. In
a patient who presents initially with arthritis and systemic
features, NSAIDS, steroids, and IL-1 blockers are reasonable
considerations depending upon the severity of symptoms
and the need for a prompt remission of symptoms. After
the initial presentation, for those patients with primarily
systemic features, we would continue IL-1 blocker and taper
steroids as tolerated. For milder cases with systemic features,
thalidomide remains an option. Tocilizumab which was
recently approved for sJIA is a choice for those patients
that have more severe disease or fail to respond to IL-1
blocking agents, but it remains an indeﬁnite commitment
to every two-week infusions at present. For children with
a predominantly polyarticular course who no longer have
fever and rash, we would consider anti-TNF agents and
methotrexate. An individualized approach for each patient
is recommended.
The newly gained knowledge and the development of
new treatments are changing the lives of children who
are suﬀering from sJIA today. Their prognosis and disease
outcomearemuchbetterthaninpreviousgenerations.There
isstillampleknowledgetobelearnedinordertocreatebetter
and more eﬀective therapies.
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